Few corners of the peptide world have generated more regulatory back-and-forth than compounded GLP-1 medications, and the rules genuinely have shifted more than once. Here's the framework that governs them.
The Shortage Exception
Under the Federal Food, Drug, and Cosmetic Act, compounding pharmacies (503A) and outsourcing facilities (503B) are generally not permitted to compound a copy of a commercially available FDA-approved drug. The major exception is when that drug is listed on the FDA's official drug shortage list, in which case compounders may legally produce versions using the same active ingredient to meet patient need the manufacturer can't currently supply. Semaglutide and tirzepatide spent extended periods on that shortage list as demand outpaced manufacturing capacity, which is what opened the door to widespread compounded versions.
What Changes When a Shortage Ends
Once the FDA determines a drug is no longer in shortage, that legal basis for compounding a copy narrows sharply. 503B outsourcing facilities generally must stop producing essentially identical copies fairly quickly after a shortage resolves, while 503A pharmacies retain somewhat more latitude to compound patient-specific, individually prescribed variations, provided they aren't just mass-producing an identical copy of the commercial product. This distinction, between a true individualized compound and a shortage-driven mass copy, is central to how the FDA and state boards evaluate compliance.
Why This Keeps Making News
Manufacturers of brand-name GLP-1 drugs have pushed for tighter restrictions on compounding, arguing patient safety and intellectual property concerns, while compounding pharmacies and patient-access advocates have argued compounded versions fill a real affordability and access gap. That tension means the regulatory line has moved more than once and is likely to keep drawing attention as manufacturing capacity, pricing, and policy continue to evolve.
What This Means Practically
If you're offered a compounded GLP-1 medication, it's reasonable to ask directly whether the underlying drug is currently listed as in shortage, whether the pharmacy is 503A or 503B licensed, and whether the product is a truly individualized formulation (different dose, added B12, combined with another active ingredient) rather than a straightforward copy of the commercial product. Those distinctions determine both the legal footing of what you're being offered and, often, how carefully it's actually being manufactured.
Where to Verify Current Status
The FDA maintains a public drug shortage database at accessdata.fda.gov that lists current shortage status for specific drugs and formulations, updated as conditions change. Checking that listing directly, rather than relying on a pharmacy's or telehealth company's own claim about shortage status, is a concrete way to confirm whether the legal basis a compounder is relying on actually still applies.